Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.